|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Cash and due from banks | ||||||||||||||||||||
| Interest-bearing bank balances | ||||||||||||||||||||
| Available-for-sale securities | ||||||||||||||||||||
| Held-to-maturity securities | ||||||||||||||||||||
| Other investments, at cost | ||||||||||||||||||||
| Loans held-for-sale | ||||||||||||||||||||
| Total | ||||||||||||||||||||
| Less, allowance for credit losses – loans | ||||||||||||||||||||
| Net loans held-for-investment | ||||||||||||||||||||
| Property and equipment – net | ||||||||||||||||||||
| Lease right-of-use asset | ||||||||||||||||||||
| Bank owned life insurance | ||||||||||||||||||||
| Other Real Estate | ||||||||||||||||||||
| Intangible assets | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES | ||||||||||||||||||||
| Deposits: | ||||||||||||||||||||
| Non-interest bearing demand deposits | ||||||||||||||||||||
| Interest bearing | ||||||||||||||||||||
| Total deposits | ||||||||||||||||||||
| Securities sold under agreements to repurchase | ||||||||||||||||||||
| Federal funds purchased | ||||||||||||||||||||
| Federal Home Loan Bank advances | ||||||||||||||||||||
| Junior subordinated debt | ||||||||||||||||||||
| Present value of estimated lease payments (lease liability) | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| SHAREHOLDERS’ EQUITY | ||||||||||||||||||||
| Common stock, par value $1.00 per share; 20,000,000 shares authorized; issued and outstanding 9,399,731 at June 30, 2026 and 7,693,215 at December 31, 2025 | ||||||||||||||||||||
| Nonvested restricted stock and stock units | ||||||||||||||||||||
| Additional paid in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total shareholders’ equity | ||||||||||||||||||||
| Total liabilities and shareholders’ equity | ||||||||||||||||||||
Loading...
